Oral Immunostimulant Market Outlook (2023 to 2033)

The global market for oral immunostimulants is set to experience a surge in value over the coming decade, with a projected CAGR of 4.1% expected to drive its worth to a valuation of US$ 30 billion by 2033. With such impressive growth rates, it's no wonder that industry experts are closely monitoring this market's every move. According to Future Market Insights, the market is expected to reach a value pool of US$ 20 billion by the end of 2023, presenting a significant opportunity for pharmaceutical companies looking to tap into this lucrative and expanding sector.

Data Points Key Statistics
Expected Market Value in 2023 US$ 20 billion
Projected Market Value in 2033 US$ 30 billion
Growth Rate (2023 to 2033) 4.1% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Boosting Immunity: The Top Drivers of the Oral Immunostimulant Market

  • Increasing prevalence of chronic diseases: As the global population ages, the incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular disease is on the rise. These conditions can weaken the immune system, leaving patients vulnerable to infections and other complications. Oral immunostimulants can help bolster immune function, making them an attractive treatment option for patients with chronic diseases.
  • Rising demand for prophylactic treatments: With the COVID-19 pandemic continuing to wreak havoc around the world, demand for prophylactic treatments that can help prevent viral infections has surged. Oral immunostimulants are one potential option for preventing infection, as they can help strengthen the body's immune response to viral pathogens.
  • Growing preference for oral medications: As patients increasingly seek more convenient and comfortable treatment options, there has been a growing preference for oral medications over injections and other forms of treatment. Oral immunostimulants can be taken in pill or liquid form, making them an attractive option for patients who prefer not to receive injections.
  • Increasing focus on preventative healthcare: With healthcare systems around the world becoming increasingly overburdened, there has been a growing focus on preventative healthcare. Oral immunostimulants can help reduce the incidence of infections and other complications, potentially reducing the burden on healthcare systems and improving patient outcomes.
  • Increasing focus on patient-centric care: As the healthcare industry continues to evolve, there has been a growing focus on patient-centric care. This approach prioritizes the needs and preferences of individual patients, and oral immunostimulants can help healthcare providers deliver more personalized and targeted care to patients.
  • Increasing use of combination therapies: As researchers learn more about the complex mechanisms involved in immune function, there has been a growing focus on combination therapies that can target multiple pathways simultaneously. Oral immunostimulants can be used in combination with other treatments, potentially improving their efficacy and reducing the risk of adverse effects.
  • Increasing awareness of the importance of immune health: As the role of the immune system in maintaining overall health becomes better understood, there has been a growing awareness of the importance of immune health. This has driven demand for treatments that can help boost immune function and support overall health and wellness.

Boosting Immunity:  Emerging Trends Shaping the Oral Immunostimulant Market

  • Increasing demand for natural and plant-based oral immunostimulants: There is a growing demand for oral immunostimulants that are derived from natural sources, such as plants, as they are perceived to be safer and more effective than synthetic alternatives.
  • Rising prevalence of autoimmune diseases: The increasing prevalence of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, is driving the demand for oral immunostimulants.
  • Growing interest in complementary and alternative medicine: There is a growing interest in complementary and alternative medicine, which includes the use of oral immunostimulants, as a way to boost overall health and well-being.
  • Expansion into emerging markets: The increasing demand for oral immunostimulants in emerging markets, such as Asia and Africa, is driving the expansion of the market into these regions.

Commonly, around 10-15% of the population suffering from a compromised immune system are more exposed to infectious diseases. Oral Immunostimulant enhances the response of the immune system to fight against tumours, infectious diseases, immunodeficiency by making the specific alteration.

The rise in the immunocompromised patient population has led to the development of various oral immunostimulant.It includes a group of synthetic and biological compounds to improve defence system of human body. There have been major focus on preparation, experimental and biological characteristics of oral immunostimulant during last two decades leading to the expansion of oral immunostimulant market.

Covid-19 is projected to impact positively on an oral immunostimulant market and estimated to generate higher revenue. In the Covid-19 pandemic, an oral immunostimulant market is expected to increase product demand due to their ability to boost immunity and protect population from infections including novel coronavirus. In addition, Covid-19 pandemic has risen awareness among the population of primary role of immunity bosting products.

Risk factors such as pollution and radiation exposure has increased risk of sensitization towards various allergens. Frequent allergic reactions due to antibiotics have led to a shift of preference towards oral immunostimulant products in an oral immunostimulant market.

In addition, rising cases of infectious diseases, allergic conditions, cancer and asthma are expected to an exponential growth of oral immunostimulant market. Unavailability of any specific treatment for viral infections such as HIV/AIDS, SARS and other flu is leading the demand of oral immunostimulants.

Generic drugs and biosimilars market competition is expected to hamper the growth of oral immunostimulant market. Discontinuation of various drugs under clinical trials has led to significant revenue loss for oral immunostimulant market due to stringent regulatory policy.

Adverse effects and stringent regulatory policies are projected to be oral immunostimulant market barriers. The global oral immunostimulant market is classified based on active, indication and sales channel.

Interferon and Interleukins are collectively expected to hold major revenue share of an oral immunostimulant market. By indication, cancer segment is expected to generate highest revenue share in an oral immunostimulant market followed by chronic infections.

Among sales channel, hospital pharmacies and retail pharmacies are projected to dominate oral immunostimulant market.Oral immunostimulant market is dominated by North America owing to availability of new therapies. Europe stands second lucrative region in an oral immunostimulant market due to an increased number of research and development activities initiated in the region.

Asia Pacific region is expected to have significant growth for oral immunostimulant market owing to increased prevalence of chronic diseases in the region. The rise in healthcare expenditure in the Latin America region is projected to grow the oral immunostimulant market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Some key players contributing in an oral immunostimulant market are

  • Pfizer Inc.
  • Step-Pharma
  • Novartis AG
  • Abbott
  • Amgen
  • Biogen
  • Johnson & Johnson
  • Merck & Co.
  • Eli Lilly and Company
  • Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company

The research report on oral immunostimulant market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on oral immunostimulant market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Regional analysis includes

  • North America (USA, Canada)
  • Latin America (Mexico, Brazil)
  • Europe (Germany, Italy, France, United Kingdom, Spain, Russia)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, ASEAN)
  • Oceania (Australia, New Zealand)
  • Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Oral Immunostimulant Market

Based on Active:

  • Thymosins
  • Interferons
  • Interleukins
  • Glucan
  • Lipopolysaccharides
  • Levamisole
  • Isoprinosine

Based On Indication:

  • Immunodeficiency Disorders
  • Chronic infections
  • Cancer
  • Organ Transplantation

Based On The Distribution Channels:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
Table of Content
  • 1. Executive Summary
  • 2. Industry Introduction, including Taxonomy and Market Definition
  • 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
  • 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
  • 5. Pricing Analysis
  • 6. Global Market Analysis and Forecast
    • 6.1. Active
    • 6.2. Indication
    • 6.3. Distribution Channels
  • 7. Global Market Analysis and Forecast, By Active
    • 7.1. Thymosins
    • 7.2. Interferons
    • 7.3. Interleukins
    • 7.4. Glucan
    • 7.5. Lipopolysaccharides
    • 7.6. Levamisole
    • 7.7. Isoprinosine
  • 8. Global Market Analysis and Forecast, By Indication
    • 8.1. Immunodeficiency Disorders
    • 8.2. Chronic infections
    • 8.3. Cancer
    • 8.4. Organ Transplantation
  • 9. Global Market Analysis and Forecast, By Distribution Channels
    • 9.1. Hospital Pharmacies
    • 9.2. Retail Pharmacies
    • 9.3. Drug Stores
    • 9.4. Online Pharmacies
  • 10. Global Market Analysis and Forecast, By Region
    • 10.1. North America
    • 10.2. Latin America
    • 10.3. Western Europe
    • 10.4. Eastern Europe
    • 10.5. Asia Pacific
    • 10.6. East Asia
    • 10.7. MEA
  • 11. North America Sales Analysis and Forecast, by Key Segments and Countries
  • 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
  • 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
  • 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
  • 15. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries
  • 16. East Asia Sales Analysis and Forecast, by Key Segments and Countries
  • 17. MEA Sales Analysis and Forecast, by Key Segments and Countries
  • 18. Sales Forecast by Active, Indication, and Distribution Channels for 30 Countries
  • 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
  • 20. Company Profile
    • 20.1. Step-Pharma
    • 20.2. Novartis AG
    • 20.3. Abbott
    • 20.4. Amgen
    • 20.5. Biogen
    • 20.6. Johnson & Johnson
    • 20.7. Merck & Co.
    • 20.8. Eli Lilly and Company
    • 20.9. Hoffmann-La Roche Ltd
    • 20.10. Bristol-Myers Squibb Company
Recommendations

Healthcare

Oral Solid Dosage Pharmaceutical Formulation Market

March 2024

REP-GB-2782

315 pages

Healthcare

Oral Controlled Release Drug Delivery Technology Market

October 2022

REP-GB-4400

222 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Oral Immunostimulant Market

Schedule a Call